Related Experiment Video

Updated: Jul 20, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis

E T H Yeh1, B V Khan

  • 1Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, and Coronary Care Unit and Vascular Research, Grady Memorial Hospital, Atlanta, GA, USA. etyeh@mdanderson.org

Journal of Thrombosis and Haemostasis : JTH
|September 12, 2006
PubMed

Insights

Inflammatory mediators signal early atherothrombosis, a condition linking atherosclerosis and ischemic events. Measuring these markers aids risk stratification and optimizes treatment for cardiovascular disease.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Vascular Biology

Background:

  • Atherothrombosis links atherosclerotic plaque development to severe ischemic vascular events like myocardial infarction and stroke.
  • Unstable atherosclerotic lesions rupture, initiating platelet activation and thrombus formation, hallmarks of atherothrombosis.
  • Atherosclerosis and atherothrombosis are increasingly understood as inflammatory diseases, suggesting inflammatory mediators as key players.

Purpose of the Study:

  • To explore the role of inflammatory mediators as early markers for atherothrombosis.
  • To assess the potential of these markers in predicting future ischemic events and improving patient risk stratification.
  • To investigate if detecting these markers can optimize current atherothrombosis management strategies.

Main Methods:

  • Review of current literature on inflammatory mediators in atherothrombosis.
  • Identification of specific molecules proposed as early markers, including C-reactive protein, CD40 ligand, myeloperoxidase, pregnancy-associated plasma protein, and plasminogen activator inhibitor-1.
  • Examination of preliminary data on the influence of antiplatelet agents and other therapies on these marker levels.

Main Results:

  • Inflammatory mediators are implicated in atherosclerotic lesion instability and rupture.
  • Several molecules (e.g., C-reactive protein, CD40 ligand) show promise as early atherothrombotic markers.
  • Initial findings suggest that existing therapies may influence the levels of these inflammatory markers.

Conclusions:

  • Inflammatory mediators represent a promising avenue for early atherothrombosis detection and risk assessment.
  • Further research is needed to validate these markers for routine clinical use in managing atherothrombosis.
  • Routine assessment of inflammatory markers could guide personalized treatment strategies for patients with atherothrombotic disease.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...